Sanofi: Oddo says group on a good momentum

(CercleFinance.com) - After the publication of quarterly results that were broadly in line with expectations, an analyst at Oddo BHF this morning said that he maintains his "buy" rating on the Sanofi share, believing that the pharmaceutical group is benefiting from dynamic growth.


The analyst says that the real issue in this publication concerns the
group's 2019 guidance. Indeed, the group expects 2019 EPS growth of
between +3% and +5% at constant exchange rates, with a positive
expected FX impact of about +1% to 2%: the consensus expects growth at
the bottom of this range, the analyst points out.

Along with its Buy rating, Oddo BHF has a target price of 91 euros,
which suggests upside potential of around 20%.



Copyright (c) 2019 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.